BRAF and melanoma: Several of these have proven successful in the clinic, including the MEK1/2 inhibitors (MEKi) trametinib and cobimetinib, and the BRAF inhibitors (BRAFi) vemurafenib and dabrafenib, all of which are approved for the treatment of BRAFV600E/K-mutant melanoma[1,2].